CryoLife, Inc. (CRY) to Release Earnings on Monday

CryoLife, Inc. (NYSE:CRY) will release its earnings data after the market closes on Monday, July 24th. Analysts expect CryoLife to post earnings of $0.10 per share for the quarter. CryoLife has set its FY17 guidance at $0.40-0.43 EPS.

CryoLife (NYSE:CRY) last released its earnings results on Wednesday, April 26th. The medical equipment provider reported $0.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.05. CryoLife had a net margin of 5.73% and a return on equity of 7.77%. The firm had revenue of $45.10 million during the quarter, compared to the consensus estimate of $44.64 million. During the same period in the prior year, the firm earned $0.10 EPS. The company’s revenue was up 4.9% compared to the same quarter last year. On average, analysts expect CryoLife to post $0.43 EPS for the current fiscal year and $0.50 EPS for the next fiscal year.

CryoLife, Inc. (CRY) opened at 19.15 on Friday. CryoLife, Inc. has a 52-week low of $11.81 and a 52-week high of $20.30. The stock’s 50 day moving average is $19.25 and its 200-day moving average is $17.96. The company has a market capitalization of $636.93 million, a P/E ratio of 62.18 and a beta of 0.99.

A number of analysts have recently commented on CRY shares. Northland Securities reiterated a “buy” rating and issued a $23.50 price target on shares of CryoLife in a research note on Friday, April 28th. Zacks Investment Research upgraded shares of CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research note on Thursday, June 8th. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $20.80.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by [[site]] and is the property of of [[site]]. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at [[permalink]].

In other news, VP Amy Horton sold 9,577 shares of CryoLife stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total value of $191,540.00. Following the completion of the sale, the vice president now directly owns 112,282 shares in the company, valued at $2,245,640. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.00% of the company’s stock.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.